Ciclo celular/Ponto de verificação
Os inibidores do ciclo celular/ponto de verificação são compostos que interrompem a progressão normal do ciclo celular, particularmente em pontos de verificação regulatórios chave. Esses inibidores são cruciais para estudar a divisão celular, entender a proliferação de células cancerígenas e desenvolver terapias anticâncer. Ao direcionar fases específicas do ciclo celular, esses inibidores podem induzir a parada do ciclo celular, levando à apoptose ou senescência em células de divisão rápida. Na CymitQuimica, oferecemos uma ampla gama de inibidores de alta qualidade do ciclo celular/ponto de verificação para apoiar sua pesquisa em biologia do câncer, biologia celular e desenvolvimento de medicamentos.
Subcategorias de "Ciclo celular/Ponto de verificação"
- Aurora Quinase(115 produtos)
- CDK(546 produtos)
- Ciclo celular/Parada(5 produtos)
- Chk(48 produtos)
- DYRK(47 produtos)
- Dinamina(27 produtos)
- Ferroptose(227 produtos)
- HSP(180 produtos)
- Integrinas(269 produtos)
- Cinesina(87 produtos)
- LIM Quinase(20 produtos)
- Microtúbulo associado(274 produtos)
- PKC(126 produtos)
- PLK(25 produtos)
- ROCK(62 produtos)
- Rho(6 produtos)
- Wee1(14 produtos)
- c-Myc(76 produtos)
Exibir 10 mais subcategorias
Foram encontrados 3905 produtos de "Ciclo celular/Ponto de verificação"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ATIC-IN-2
CAS:ATIC-IN-2 (Compound 1) is a competitive inhibitor of the bifunctional enzyme AICAR Tfase/IMPCH (ATIC), binding to inosine monophosphate cyclohydrolase (IMPCH) with a Ki of 0.13 μM.Fórmula:C4H4N4O3SCor e Forma:SolidPeso molecular:188.165CDK9-IN-38
CAS:CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM for wild-type CDK9 and 3.3 nM for the L156F mutant. It effectively inhibits tumor growth both in vitro and in vivo.Fórmula:C22H23N5O3SCor e Forma:SolidPeso molecular:437.515CDK6-IN-1
CAS:CDK6-IN-1 (compound 4i) is an inhibitor of CDK6 that suppresses cell growth and induces cell cycle arrest at the G1 phase.Fórmula:C30H23N5Cor e Forma:SolidPeso molecular:453.54CIB-L43
CAS:CIB-L43 is a oral TRBP inhibitor, inhibit miR-21, increase PTEN and Smad7, and block the AKT and TGF-β，inhibit proliferation and migration.Fórmula:C15H16N2O3SPureza:99.64%Cor e Forma:SolidPeso molecular:304.36CDK7-IN-31
CAS:CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.Fórmula:C27H32F5N6O2PCor e Forma:SolidPeso molecular:598.55DNA polymerase-IN-6
CAS:DNA polymerase-IN-6 (Compound 27) exhibits inhibitory activity against DNA polymerase, with EC50 values of 0.33 µM for HCMV, 1.9 µM for HSV-1, 0.76 µM for HSV-2, and 0.066 µM for EBV.Fórmula:C26H28ClFN8O4Cor e Forma:SolidPeso molecular:571.003Haspin-IN-1
Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.Fórmula:C12H8N4O2SCor e Forma:SolidPeso molecular:272.28β-catenin-IN-8
CAS:β-catenin-IN-8 (Compound 25) is an inhibitor of β-catenin. It effectively lowers the levels of both β-catenin and c-Myc proteins and suppresses Wnt target genes (Fgf20 and Sall4). Additionally, β-catenin-IN-8 exhibits anticancer activity against colorectal cancer and possesses metabolic stability.Fórmula:C15H12ClN3O2SCor e Forma:SolidPeso molecular:333.79(Rac)-Plevitrexed
CAS:(Rac)-Plevitrexed is a racemate of Plevitrexed. Plevitrexed is an orally active and potent inhibitor of thymidylate synthase (TS).Fórmula:C26H25FN8O4Pureza:98%Cor e Forma:SolidPeso molecular:532.53MtTMPK-IN-5
MtTMPK-IN-5 inhibits Mtb TMPK with IC50 of 34 μM and fights tuberculosis with MIC of 12.5 μM, aiding TB research.Fórmula:C21H23N5O2Cor e Forma:SolidPeso molecular:377.44PT109
CAS:PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.Fórmula:C23H31N3OS2Cor e Forma:SolidPeso molecular:429.64FT709
CAS:FT709 is a selective USP9X deubiquitinating enzyme inhibitor (IC50=82 nM) that reduces Makorin and ZNF598 levels, impairing ribosomal quality control pathways.Fórmula:C23H22N4O7SCor e Forma:SolidPeso molecular:498.51CHK1-IN-2
CAS:CHK1-IN-2 is an inhibitor of checkpoint kinase 1 (CHK1; IC50: 6 nM).Fórmula:C20H22N4OSPureza:98%Cor e Forma:SolidPeso molecular:366.48CLK1/2-IN-1
CAS:CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.Fórmula:C21H20F3N7OPureza:98%Cor e Forma:SolidPeso molecular:443.42PLK1-IN-11
CAS:PLK1-IN-11 (Cluster 4, 16953209) is a PLK1 inhibitor with an IC50 of 1 μM. It is applicable in research on various cancers such as pancreatic, ovarian, breast, and non-small cell lung cancer.Fórmula:C12H11N5OCor e Forma:SolidPeso molecular:241.249Antiangiogenic agent 2
Antiangiogenic agent 2 (compound 3b) is a potent inhibitor of thymidine phosphorylase (IC50: 39.71 μM) and exhibits anti-angiogenic effects.
Fórmula:C26H26FN3O4Cor e Forma:SolidPeso molecular:463.5CDK1-IN-6
CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.Fórmula:C21H22N4OCor e Forma:SolidPeso molecular:346.43LIMK-IN-2
CAS:LIMK-IN-2 (Compound 52), an LIMK inhibitor, has demonstrated potential anti-angiogenic activity by suppressing the cell migration of osteosarcoma and cervical cancer cells [1].Fórmula:C28H27N5O2Cor e Forma:SolidPeso molecular:465.55Mps1-IN-8
CAS:Mps1-IN-8, a Mps1 inhibitor, can be utilized in the study of various tumors [1].Fórmula:C35H47N8O6PCor e Forma:SolidPeso molecular:706.77EFdA-TP tetrasodium
CAS:EFdA-TP tetrasodium is a potent HIV-1 inhibitor that blocks DNA synthesis as an ICT or DCT.Fórmula:C12H11FN5Na4O12P3Pureza:98%Cor e Forma:SolidPeso molecular:621.12iPAF1C
CAS:iPAF1C is a powerful inhibitor of the polymerase-associated factor 1 complex (PAF1C) and exhibits anti-HIV activity [1].
Fórmula:C27H26BrFN4OCor e Forma:SolidPeso molecular:521.42CD 10899
CAS:CD 10899, a hydroxylated metabolite of Volasertib, is pharmacologically active against Polo-like kinase 1 (PLK1) with an IC50 of 6 nM. Volasertib is an orally active, highly potent, and ATP-competitive PLK1 inhibitor. CD 10899 can be used for cancer research [1].Fórmula:C34H50N8O4Cor e Forma:SolidPeso molecular:634.81UMPK ligand 1
CAS:UMPK ligand 1 (ZINC07785412) serves as a ligand for uridine monophosphate kinase (UMPK).
Fórmula:C15H22N4O5SCor e Forma:SolidPeso molecular:370.424TMX-3013
CAS:TMX-3013 is a CDK inhibitor that targets multiple cyclin-dependent kinases, specifically suppressing the activity of CDK1, CDK2, CDK4, CDK5, and CDK6 with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM respectively. Additionally, TMX-3013 is utilized in the synthesis of PROTACs, which use polyethylene glycol (PEG) as a linker and Thalidomide as the CRBN-recruiting arm.Fórmula:C17H14BrFN6O3SCor e Forma:SolidPeso molecular:481.3MtTMPK-IN-8
MtTMPK-IN-8 inhibits MtbTMPK, has low cytotoxicity, shows 0.78-9.4 μM activity against Mycobacterium, useful for tuberculosis research.Fórmula:C24H24N6O7Cor e Forma:SolidPeso molecular:508.48CHK1-IN-11
CAS:CHK1-IN-11 (Compound 1) is an orally active inhibitor of checkpoint kinase 1 (CHK1). It is utilized in research focused on cancers with oncogene amplification.Fórmula:C20H22N8O2Cor e Forma:SolidPeso molecular:406.44CDK4/6-IN-3
CAS:CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.Fórmula:C25H31FN8Pureza:98%Cor e Forma:SolidPeso molecular:462.57WEE1 degrader 1
WEE1degrader 1 (Compound 10) functions as a Wee1 degrader, exhibiting a DC50 value of 1.5 nM against Wee1. This compound also possesses anticancer properties that inhibit cell proliferation.Fórmula:C30H31N5O3Cor e Forma:SolidPeso molecular:509.6AR-13324 M1 metabolite
CAS:AR-13324 M1 metabolite is a hydrolysis metabolite of AR-13324 mesylate.Fórmula:C19H19N3O2Pureza:98%Cor e Forma:SolidPeso molecular:321.37LIMK1 inhibitor 1
CAS:LIMK1 inhibitor1 (compound 24) is a LIMK1 inhibitor, potentially useful for cancer research.Fórmula:C12H15N3S2Cor e Forma:SolidPeso molecular:265.398Dyrk1A-IN-8
CAS:Dyrk1A-IN-8 is an active molecule that can be used in life science related research. The CAS number of Dyrk1A-IN-8 is 101578-13-6.Fórmula:C17H21N3OCor e Forma:SolidPeso molecular:283.37PLK1-IN-5
CAS:PLK1-IN-5, a potent PLK1 inhibitor, has an IC50 of less than 500 nM and demonstrates anticancer effects (WO2008113711A1; compound I-4) [1].Fórmula:C28H39N7O3Cor e Forma:SolidPeso molecular:521.65(R)-CSN5i-3
CAS:(R)-CSN5i-3 is CSN5i-3 of the R configuration.Fórmula:C28H29F2N5O2Pureza:99.76% - 99.97%Cor e Forma:SolidPeso molecular:505.562'-O-MOE-GTP
CAS:2'-O-MOE-GTP is a nucleotide analog utilized in the synthesis of oligonucleotides.Fórmula:C13H22N5O15P3Cor e Forma:SolidPeso molecular:581.26CDK1-IN-3
CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.Fórmula:C28H25ClF3N5O2Cor e Forma:SolidPeso molecular:555.98CHK1 inhibitor
CAS:CHK1 inhibitor (GDC-0575 analog) is a CHK1 inhibitor.Fórmula:C17H21BrN4OPureza:98%Cor e Forma:SolidPeso molecular:377.28ROCK-IN-11
CAS:ROCK-IN-11 (example 94) is an effective inhibitor of ROCK1 and ROCK2, with an IC50 of ≤ 5 μM, and plays a significant role in cancer research.Fórmula:C22H20N4O4SCor e Forma:SolidPeso molecular:436.484SCH-1473759
CAS:SCH-1473759 is an inhibitor of the aurora (IC50s: 4 and 13 nM for Aurora A and B, respectively).Fórmula:C20H26N8OSPureza:98%Cor e Forma:SolidPeso molecular:426.545-Methylcytosine hydrochloride
CAS:5-Methylcytosine hydrochloride plays a critical role in regulating gene expression, promoting genomic imprinting, and inhibiting transposon factors. It is also closely associated with translation fidelity and tRNA recognition.Fórmula:C5H8ClN3OCor e Forma:SolidPeso molecular:161.59AB25583
CAS:AB25583 is a small molecule inhibitor of Polθ helicase (Polθ-hel) with an IC50 of 6 nM. It selectively kills cells deficient in BRCA1/2 and synergizes with Olaparib in cancer cells harboring pathogenic BRCA1/2 mutations. AB25583 can be utilized in tumor research.Fórmula:C22H17ClN4O3SCor e Forma:SolidPeso molecular:452.91Cdc7-IN-18
CAS:Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).Fórmula:C19H21N5OSCor e Forma:SolidPeso molecular:367.47Cdc7-IN-19
CAS:Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.40KL-50
CAS:KL-50, a selective toxin, effectively targets tumors deficient in the DNA repair protein O6-methylguanine-DNA-methyltransferase (MGMT), which corrects O6-alkylguanine lesions. This compound induces both DNA damage response pathways and cell cycle arrest in MGMT-deficient cells, regardless of mismatch repair (MMR) status. KL-50 shows promise in the study of brain tumors lacking MGMT.Fórmula:C7H7FN6O2Cor e Forma:SolidPeso molecular:226.17GR 83895
CAS:GR 83895 is an antagonist of prototype fibrinogen receptor.Fórmula:C29H39N9O8SPureza:98%Cor e Forma:SolidPeso molecular:673.74DHX9-IN-19
CAS:DHX9-IN-19 (compound 3) is an orally active inhibitor of DHX9, playing a significant role in cancer research.Fórmula:C20H21ClN4O4S2Cor e Forma:SolidPeso molecular:480.988IXA62
CAS:IXA62 is an orally active, selective IRE1/XBP1s agonist (EC50= 0.31 μM) that can reduce Aβ secretion.Fórmula:C24H23N3O3Cor e Forma:SolidPeso molecular:401.458DYR530
CAS:DYR530 is a ligand for the target protein (protein kinase DYRK1A) of PROTAC.Fórmula:C23H24FN7Cor e Forma:SolidPeso molecular:417.485-Fluorouridine 5'-phosphate
CAS:5-Fluorouridine 5'-phosphate acts as an ODCase (uridine 5'-monophosphate decarboxylase) inhibitor, exhibiting a Ki value of 98 µM for human ODCase and 645 µM for Methanococcus jannaschii ODCase. This compound also shows inhibitory activity on leukemia and lymphoma cell lines, making it useful for cancer research studies.Fórmula:C9H12FN2O9PCor e Forma:SolidPeso molecular:342.172AJI-100
CAS:AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).Fórmula:C17H14FN5OCor e Forma:SolidPeso molecular:323.32Lisavanbulin
CAS:Lisavanbulin (BAL-101553) is a prodrug of Avanbulin (BAL 27862), a microtubule-targeting agent. It exhibits antitumor activity, particularly effective against tumors with high expression of end-binding protein 1.Fórmula:C26H29N9O3Cor e Forma:SolidPeso molecular:515.57
